Luckin Coffee Inc. has filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission, including audited consolidated financial statements prepared under U.S. GAAP for the fiscal year ending December 31, 2025. This filing provides transparency on the company’s financial performance and is accessible on the SEC and Luckin Coffee’s investor relations websites. The report follows the company’s recent financial results announcement showing significant revenue growth and customer base expansion. Investors can review the detailed financials and forward-looking statements outlining potential risks and growth strategies for the future.
Kazia Therapeutics is progressing its main cancer drug candidate, paxalisib, into Phase 2 trials for colorectal cancer and planning a new breast cancer study. The company recently raised $40 million to support these developments and maintains a stron...
Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa with a new price target of $18.50 following a major licensing deal with GSK. The agreement grants GSK exclusive rights to commercialize HCM's experimental cancer therapy ...
Duluth Holdings reported a strong Q2 earnings per share (EPS) of $0.50, far exceeding the consensus estimate of -$0.01, largely due to $0.44 per share from tariff refunds. Revenue reached $121.39 million, beating estimates but declining from the prev...
Estée Lauder Companies recently appointed new brand leaders, signaling strategic shifts in its competitive beauty market. An insider executive sold 7,766 shares worth over $802,000, leaving no remaining holdings. The company shows a high P/E ratio of...
HUTCHMED's shares surged 17.77% after announcing a major licensing deal with GSK for its preclinical cancer drug HMPL-A830. GSK gets exclusive rights outside Greater China, paying $110 million upfront plus up to $1.295 billion in milestone payments. ...
